---
title: A brave new framework for glioma drug development
date: '2024-10-03'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39362262/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20241004202135&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Patients with brain tumours are motivated to participate in clinical
  trials involving repeat tissue sampling. Normalising the use of neoadjuvant and
  staged surgical trials necessitates collaboration among patients, regulatory agencies,
  and researchers. Initial and repetitive tissue sampling plays a crucial role in
  enhancing our understanding of resistance mechanisms and vulnerabilities in brain
  tumour therapy. Standardising biopsy techniques and ensuring technical uniformity
  across ...
disable_comments: true
---
Patients with brain tumours are motivated to participate in clinical trials involving repeat tissue sampling. Normalising the use of neoadjuvant and staged surgical trials necessitates collaboration among patients, regulatory agencies, and researchers. Initial and repetitive tissue sampling plays a crucial role in enhancing our understanding of resistance mechanisms and vulnerabilities in brain tumour therapy. Standardising biopsy techniques and ensuring technical uniformity across ...